Company Information

  

Address: ATTN: CHIEF FINANCIAL OFFICER
950 WINTER STREET 
City: WALTHAM 
State: MA 
Zip Code: 02451 
Telephone: 617-551-4000 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

Unless otherwise provided in this report, all references in this report to "we," "us," "Radius," "our company," "our," or the "Company" refer to Radius Health, Inc. and our subsidiaries. Overview We are a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology. In April 2017, our first commercial product, TYMLOSTM (abaloparatide) injection, was approved by the U.S. Food and Drug Administration ("FDA") for the treatment of postmenopausal women with osteoporosis at high risk for fracture defined as history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. In May 2017, we commenced U.S. commercial sales of TYMLOS and, as of February 2018, TYMLOS was available and covered for approximately 259 million U.S.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
03/2018-5.85NAN/E
12/2017-5.80NAN/E
09/2017-5.43NAN/E
03/2017-4.62NAN/E
12/2016-4.24NAN/E
09/2016-3.81NAN/E
06/2016-3.43NAN/E
03/2016-3.03NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2017 Leverage 2017
Net Inc/Comm Equity-0.23Total Liab/Total Assets0.48
Net Inc/Total Assets-0.55Total Liab/Inv Cap0.54
Net Inc/Inv Cap-0.62Total Liab/Comm Equity0.20
Pretax Inc/Net Sales-11.50Interest Coverage Ratio-29.64
Net Inc/Net Sales-11.50Curr Debt/EquityNA
Cash Flow/Net Sales-9.35LTD/Equity0.69
SG&A/NetSales8.44Total Debt/Equity0.69
Asset Utilization   Liquidity  
Net Receivables Turnover9.96Quick Ratio4.96
Inventory Turnover0.61Current Ratio5.04
Inventory Day Sales0.00Net Rec/Curr Assets0.02
Net Sales/Work Cap0.10Inv/Curr Assets0.02
Net Sales/PP&E3.57  

Income Statement (Millions)

  3/31/2018 12/31/2017 9/30/2017 6/30/2017
Total Revenues(Net Sales) 14.55 7.66 13.47 0.98
Cost of Goods Sold 1.29 0.77 0.45 0.11
Selling & Admin Exps 48.03 50.73 47.72 50.12
Operating Income -57.62 -66.75 -55.70 -68.90
Interest Exp 5.57 5.54 2.76 0.00
Pretax Income -61.56 -71.02 -57.84 -68.44
Other Income 1.63 1.26 0.62 0.46
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -61.56 -71.02 -57.84 -68.44

Balance Sheet (Millions)

Assets 3/31/2018 12/31/2017 9/30/2017 6/30/2017
Cash & Short Term Investments 235.60 253.33 468.13 214.76
Receivables - Total 8.05 4.44 11.68 1.21
Inventories - Total 5.44 4.37 3.07 1.64
Total Current Assets 257.75 269.51 490.69 223.55
Net Property, Plant & Equipment 5.76 6.20 7.31 6.74
Total Assets 404.00 461.66 506.94 239.43
Liabilities        
Accounts Payable 39.37 53.43 38.13 31.77
Debt in Current Liabilities NA NA NA NA
Total Current Liabilities 39.37 53.43 38.13 31.77
Long-Term Debt 169.28 166.01 162.76 NA
Total Liabilities 208.82 219.62 201.10 32.11
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock NA NA NA NA
Common Stock 0.01 0.00 0.00 0.00
Retained Earnings -943.84 -882.28 -811.27 -753.42
Treasury Stock NA NA NA NA
Total Stockholders' Equity 195.18 242.04 305.84 207.32
Total Liabilities and Stockholders' Equity 404.00 461.66 506.94 239.43

Cash Flow Summary (Millions)

Categories 3/31/2018 12/31/2017 9/30/2017 6/30/2017
Net Cash Provided by Operating Activities -70.23 -39.59 -54.14 -60.19
Net Cash Provided by Investing Activities -0.56 -290.09 56.67 18.44
Net Cash Provided by Financing Activities 8.32 1.31 309.30 2.23

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20130.00-60.69--
12/20140.00-62.48-4.04
12/20150.00-101.53-2.56
12/20160.00-182.80-4.24
12/201722.11-254.24-5.80
Growth RatesInfinity----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional03/31/1816356,295--




Report Date : 6/18/2018

Powered By Edgar Online © 2018EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.